MNKDMannKind Corporation

$813M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M-18.8% YoY

Gross Profit

$6M31.6% margin

Operating Income

-$20M-108.3% margin

Net Income

-$29M-153.6% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

+57.6%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$29M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$286M

Total Liabilities

$533M

Stockholders' Equity

-$247M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$23M	-18.8%
Gross Profit	$6M	$13M	-55.2%
Operating Income	-$20M	-$10M	-99.1%
Net Income	-$29M	-$36M	+18.3%

Revenue Segments

Product Sales

$17M55%

Product

$13M40%

Service

$1M4%

Royalty

$304,0001%

MNKD Q2 2022 Earnings — MannKind Corporation Revenue & Financial Results | Market Cap Arena